Elanix Biotechnologies AG Logo

Elanix Biotechnologies AG

ELN | F

Overview

Corporate Details

ISIN(s):
DE000A0WMJQ4
LEI:
391200SYNFFL0NPAJK90
Country:
Germany
Address:
Hanauer Landstrasse 291, 60314 Frankfurt am Main
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Elanix Biotechnologies is a tissue regeneration company. We develop and commercialize products for acute wound care, dermatological and gynecological applications, as well as providing cell technology services. The company was founded in 2012 as a spin-off from the University Hospital of Lausanne (CHUV), Switzerland, to commercialize a patented progenitor cell technology. Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing. Elanix owns GMP certified Master and Working cell banks containing vast quantities of cells. The Company is headquartered in Epalinges, Switzerland with offices in Hamburg and listed on the Frankfurt stock exchange under the symbol ELN.

Social Media

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Elanix Biotechnologies AG and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2023-02-14 10:05
Board/Management Information
Elanix Biotechnologies AG: RESIGNATION AND NOMINATION IN THE SUPERVISORY BOARD
English 5.1 KB
2022-12-21 18:30
Major Shareholding Notification
German 4.6 KB
2022-12-19 12:30
Declaration of Voting Results & Voting Rights Announcements
German 14.0 KB
2022-12-06 13:00
Declaration of Voting Results & Voting Rights Announcements
German 14.2 KB
2022-12-05 10:15
Declaration of Voting Results & Voting Rights Announcements
German 13.7 KB
2022-12-02 15:15
Declaration of Voting Results & Voting Rights Announcements
German 14.0 KB
2020-02-27 12:19
Board/Management Information
ELANIX BIOTECHNOLOGIES AG: RESIGNATION AND NOMINATION IN THE SUPERVISORY BOARD …
English 4.8 KB
2019-10-03 10:34
Report Publication Announcement
English 2.0 KB
2019-08-21 16:49
Report Publication Announcement
English 2.0 KB
2019-08-19 16:58
Report Publication Announcement
English 2.0 KB
2019-07-26 13:51
Declaration of Voting Results & Voting Rights Announcements
English 14.0 KB
2019-07-23 16:59
Declaration of Voting Results & Voting Rights Announcements
English 14.0 KB
2019-07-22 10:17
Declaration of Voting Results & Voting Rights Announcements
English 14.0 KB
2019-06-25 14:03
Declaration of Voting Results & Voting Rights Announcements
English 13.9 KB
2019-06-25 13:57
Major Shareholding Notification
English 13.9 KB

Automate Your Workflow. Get a real-time feed of all Elanix Biotechnologies AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Elanix Biotechnologies AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Cantargia Logo
Develops antibody-based drugs targeting IL1RAP for cancer and inflammatory diseases.
Sweden CANTA
Captor Therapeutics S.A. Logo
Develops TPD drugs for oncology and autoimmune disorders, targeting 'undruggable' proteins.
Poland CTX
Developing engineered cellular medicines for regenerative treatment of heart failure.
United Kingdom N/A
Cellectis Logo
Biopharma using gene-editing to create off-the-shelf CAR T-cell cancer therapies.
France ALCLS
Celyad Oncology SA Logo
Clinical-stage biotech developing allogeneic & autologous CAR T-cell therapies for cancer.
Belgium CYAD
Cereno Scientific AB Logo
Clinical-stage biotech developing treatments for rare cardiovascular & pulmonary diseases.
Sweden CRNO
Ceres Power Holdings PLC Logo
Licensing solid oxide tech (SOFC/SOEC) for clean power and green hydrogen to global partners.
United Kingdom CWR
Cessatech A/S Logo
Develops non-invasive pain relief, like a nasal spray, for children.
Denmark CESSA
CHOSA Oncology AB Logo
Develops diagnostics and drug delivery for personalized cancer therapy.
Sweden CHOSA
Cinclus Pharma Holding AB Logo
Late-stage pharma developing a next-gen P-CAB drug for severe GERD and H. pylori.
Sweden CINPHA

Talk to a Data Expert

Have a question? We'll get back to you promptly.